



NDA 206352
NDA 21567 S-035

**NDA APPROVAL
SUPPLEMENT APPROVAL**

Bristol-Myers Squibb Company
Attention: Lisa Percival
Director, Global Regulatory Strategy
5 Research Parkway, Mailstop 2CW-506
Wallingford, CT 06492

Dear Ms. Percival:

Please refer to your New Drug Application (NDA) dated and received December 2, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for REYATAZ® (atazanavir) oral powder, 50 mg per packet.

Please also refer to your Supplemental New Drug Application (sNDA) dated and received December 2, 2013, submitted under section 505(b) of the FDCA for REYATAZ® (atazanavir) capsules, 150 mg, 200 mg and 300 mg.

We acknowledge receipt of your amendments on the following dates:

NDA 206352

December 23, 2013	April 15, 2014
January 17, 2014	April 18, 2014
February 19, 2014	May 7, 2014
February 21, 2014	May 8, 2014
February 26, 2014	May 15, 2014 (2)
March 4, 2014	June 2, 2014
March 12, 2014	

NDA 21567 S-035

December 3, 2013
February 19, 2014
June 2, 2014

The new drug application, NDA 206352, provides for the use of a new dosage form, REYATAZ® (atazanavir) oral powder, in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg.

The Prior Approval supplemental new drug application, sNDA 21567 S-035, updates the shared REYATAZ® (atazanavir) labeling with information on use of the new dosage form, REYATAZ® (atazanavir) oral powder.

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 206352.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the products with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for REYATAZ® (atazanavir) oral powder (NDA 206352) for ages < 3 months of age because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric group due to risk of kernicterus.

We reference your waiver previously granted on July 6, 2004, for REYATAZ® (atazanavir) capsules (NDA 21567) for ages < 3 months of age because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric group due to risk of kernicterus.

We also reference discussion and concurrence during the November 19, 2012, preNDA meeting for atazanavir oral powder that you would complete dosing studies for the 5 to < 10 kg weight cohort and submit the dosing recommendations in a supplement to the NDA.

We are deferring submission of your pediatric studies for pediatric patients who are 3 months and older who weigh 5 to < 10 kg under NDA 206352 because the product is ready for approval for pediatric patients who weigh 10 to < 25 kg and the pediatric study in the lower weight group has not been completed to determine dosing recommendations.

Your deferred pediatric study required by section 505B(a) of the FDCA is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. This required study is listed below.

- 2153-1 Deferred pediatric study under PREA to evaluate atazanavir oral powder pharmacokinetics, safety, and treatment response in HIV-1 infected pediatric patients 3 months and older who weigh 5 kg to less than 10 kg.

Study Completion: October 2014
Final Report Submission: June 2015

Reports of this required pediatric postmarketing study must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

We note that you have fulfilled the pediatric study requirement (PMR 1244-1) for ages 3 months to 18 years.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments under NDA 206352:

- 2153-2 Development of a new, more sensitive dissolution method, dissolution acceptance criterion proposal, and data supporting the newly proposed dissolution method and acceptance limit.

The timetable you submitted on May 15, 2014, states that you will conduct this study according to the following schedule:

Final Report Submission: September 2015

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sammie Beam RPh, Regulatory Project Manager, at (301) 796-0080.

Sincerely,

{See appended electronic signature page}

Jeffrey S. Murray, MD, MPH
Deputy Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
06/02/2014